


At a Glance

Pharmaceuticals

¥52,554 million (82.7%)

Our core products in this segment include drugs that treat urological diseases, inflammation, allergies, hematologic malignancies, cardiovascular and metabolic diseases and gastrointestinal disorders. We have high hopes for Vidaza®, a new and highly effective treatment for myelodysplastic syndrome that we began selling in March 2011.



Drugs for Urological Diseases



- **Eviprostat®**
(Herbal extracts)
Remedy for benign prostatic hypertrophy
- **Bladderon®**
(Flavoxate hydrochloride)
Remedy for pollakisuria
- **Estracryt**
(Estramustine sodium phosphate)
Remedy for prostate cancer
- **Cialis®**
Remedy for erectile dysfunction

Eviprostat®, a remedy for benign prostatic hypertrophy, has been prescribed for many years, primarily by urologists. We began selling erectile dysfunction (ED) treatment Cialis® in July 2009, and sales have been growing.

Net Sales (Millions of yen)



Drugs for Inflammation and Allergy



- **Hyphen®**
(Etodolac)
Non-steroidal analgesic and anti-inflammatory agent
- **Erizas®**
Remedy for allergic rhinitis
- **Livostin®**
Remedy for allergy
- **Baynas®**
Remedy for allergic rhinitis
- **Azunol® Gargle 4%**
Gargling solution containing azulene

When we introduced Erizas® for allergic rhinitis in December 2009, it was the first powdered steroid preparation in Japan to effectively relieve symptoms through once-a-day administration. In addition to only requiring one application per day, allergy sufferers appreciate the convenience of the product's special spray device that makes it possible to spray both nostrils at once.

Net Sales (Millions of yen)



Drugs for Hematologic Malignancies



- **Vidaza®**
Remedy for myelodysplastic syndromes
- **Cycloide**
(Cytarabine)
Remedy for acute leukemia and solid cancer
- **Cycloide N**
(Cytarabine)
Remedy for relapsed and refractory acute leukemia and malignant lymphoma
- **Trisenox®**
Remedy for relapsed and refractory acute promyelocytic leukemia
- **Amnolake®**
Remedy for relapsed and refractory acute promyelocytic leukemia

Vidaza®, the myelodysplastic syndrome (MDS) treatment that we launched in March 2011, is the only medicine in the world that has been shown to prolong survival in MDS patients. Its high degree of effectiveness makes it a very promising product.

Net Sales (Millions of yen)



Drugs for Cardiovascular and Metabolic Diseases




- **Selectol**
(Celiaprolol hydrochloride)
Remedy for hypertension and angina pectoris
- **Glycoran**
(Metformin hydrochloride)
Remedy for diabetes
- **Adcirca®**
Pulmonary arterial hypertension treatment agent

Launched in December 2009, Adcirca® is a remedy for pulmonary arterial hypertension, which is considered to be an intractable disease. Taken orally once a day, it works by inhibiting phosphodiesterase-5. Adcirca®'s market share expanded greatly in the fiscal term ended March 2011.

Net Sales (Millions of yen)



Net Sales (Millions of yen)



Functional Food ¥10,970 million (17.3%)

Our in-house functional food company leverages the sophisticated manufacturing technology and quality know-how accumulated by our pharmaceutical operations to contribute to human health through the supply of functional foods and ingredients. With safety and reliability as our top priorities, we supply highly original and helpful functional foods and ingredients.

Drugs for Gastrointestinal Disorders



- **Gaslon N®**
(Irsogladine maleate)
Remedy for gastric ulcer and gastritis
- **Portolac®**
(Lactitol hydrate)
Remedy for hyperammonaemia

Although the market for protective factor potentiators has contracted slightly, we are seeing further growth in sales of our mucosal protective Gaslon N®, a remedy for gastric ulcers and gastritis, thanks to new evidence of its efficacy.

Net Sales (Millions of yen)



Others Including the Proceeds from Intellectual Property Rights



- **Lunabell®**
Remedy for dysmenorrhea
- **Cephadol®**
(Difenidol hydrochloride)
Remedy for vertigo
- **Tramal®**
Remedy for cancer pain
- **Prulifloxacin**
Synthetic antibacterial agent

After Lunabell® was put on the market in July 2008 as a remedy for dysmenorrhea resulting from endometriosis, Japanese insurance programs covered its use and it achieved good market penetration. Since we obtained approval to list functional dysmenorrhea as an additional indication in December 2010, sales have been growing even more.

Net Sales (Millions of yen)



- Health food ingredients
- Preservatives
- Protein preparations
- Nutritional ingredients
- Seasonings and spices
- Sterilization cleaning agents



Despite ongoing harsh business conditions in the processed foods and health foods industries, in the fiscal year through March 2011 Nippon Shinyaku enjoyed growth in sales of health food ingredients, preservatives, and protein preparations.

Net Sales (Millions of yen)

